Hypothesis

The circadian clock directly times the expression and activity of the lysosomal protease cathepsin L (CTSL) to drive rhythmic clearance of senescence‑associated secretory phenotype (SASP) factors and to limit collagen cross‑linking via lysyl oxidase (LOX). Loss of this temporal gating—whether through genetic disruption of BMAL1/CLOCK or age‑related dampening of clock amplitude—results in sustained SASP accumulation, aberrant extracellular matrix (ECM) stiffening, and chronic inflammation, thereby accelerating multiple SENS hallmarks of aging.

Mechanistic Rationale

1. Transcriptional control – BMAL1/CLOCK heterodimers bind E‑box elements in the promoter of the Ctsl gene, driving a ~24‑hour oscillation in cathepsin L mRNA and protein levels in liver, muscle, and skin (supported by chromatin‑seq data showing rhythmic BMAL1 occupancy at lysosomal gene loci).
2. Proteostatic flux – Cathepsin L activity peaks during the active phase, coinciding with heightened autophagic flux, enabling selective degradation of secreted SASP components (e.g., IL‑6, MMP‑9) before they can engage downstream receptors.
3. ECM feedback – When cathepsin L rhythm is blunted, SASP proteases persist, activating latent TGF‑β and upregulating LOX transcription via SMAD signaling, leading to increased collagen cross‑linking and tissue stiffening.
4. Age‑related decoupling – In aged tissues, reduced BMAL1 binding (as observed in epidermal BMAL1/YAP re‑programming) diminishes Ctsl oscillation, uncoupling SASP clearance from the circadian cycle and creating a feed‑forward loop of inflammation and ECM remodeling.

Testable Predictions

• Prediction 1: In wild‑type mice, cathepsin L activity in liver and skeletal muscle will show a robust circadian rhythm (peak ~ZT6‑ZT10) that is abolished in Bmal1‑KO or Clock‑Δ19 mutants.
• Prediction 2: Pharmacological enhancement of cathepsin L activity at the predicted peak time (e.g., timed delivery of a cathepsin L activator) will reduce circulating SASP factors and lower tissue LOX‑mediated cross‑links compared with vehicle or mistimed dosing.
• Prediction 3: Chronic mistimed feeding (e.g., high‑fat diet ad libitum) will dampen Ctsl rhythm, accelerate SASP accumulation, and shorten lifespan; rescuing the rhythm via time‑restricted feeding will restore cathepsin L oscillation and improve healthspan.

Experimental Approach

• In vivo: Use Bmal1 floxed mice crossed with tissue‑specific Cre drivers (muscle, liver, epidermis) to generate conditional knockouts; monitor cathepsin L activity via fluorogenic substrates every 4 h over 48 h. Simultaneously measure SASP cytokines (ELISA), LOX activity (hydroxylysine pyridinoline assay), and collagen cross‑linking (second‑harmonic generation imaging).
• Intervention: Administer a cathepsin L‑activating peptide (or small‑molecule allosteric activator) either at the predicted activity peak or at the trough; assess SASP burden, ECM stiffness (atomic force microscopy), and functional outcomes (grip strength, treadmill endurance, skin elasticity).
• Human relevance: Analyze peripheral blood mononuclear cells from young vs. older volunteers for circadian cathepsin L mRNA (qPCR) and activity; correlate with plasma SASP markers and pulse‑wave velocity (arterial stiffness proxy).

Falsifiability

If cathepsin L activity does not exhibit a circadian rhythm in wild‑type tissues, or if timed activation fails to reduce SASP/LOX signatures despite robust target engagement, the hypothesis would be refuted. Conversely, confirmation would position circadian regulation of lysosomal proteostasis as a direct, repair‑oriented anti‑aging lever that can be harnessed via chronopharmacology.